RSPI (RespireRx Pharmaceuticals) Cyclically Adjusted PB Ratio: (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RSPI RespireRx Pharmaceuticals Inc RSPI
12 GF Score
Price $0.00
View Full Analysis

What is RespireRx Pharmaceuticals Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


RespireRx Pharmaceuticals  (OTCPK:RSPI) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


RespireRx Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms


RespireRx Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for RespireRx Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RespireRx Pharmaceuticals Cyclically Adjusted PB Ratio Chart

RespireRx Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

RespireRx Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

RSPI vs CNBX, NAVB, IPIX: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, RespireRx Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RespireRx Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RespireRx Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where RespireRx Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


RSPI
12GF Score
RespireRx Pharmaceuticals Inc RSPI
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RespireRx Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

RespireRx Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 is calculated as:

For example, RespireRx Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Sep. 2023 was:

Adj_Book=Book Value per Share/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.044/307.7890*307.7890
=-0.044

Current CPI (Sep. 2023) = 307.7890.

RespireRx Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201312 -95.682 233.049 -126.368
201403 -52.113 236.293 -67.881
201406 -50.935 238.343 -65.776
201409 -47.785 238.031 -61.789
201412 -43.577 234.812 -57.120
201503 -45.270 236.119 -59.011
201506 -22.945 238.638 -29.594
201509 -16.184 237.945 -20.934
201512 -20.808 236.525 -27.077
201603 -26.569 238.132 -34.341
201606 -18.401 241.018 -23.499
201609 -24.099 241.428 -30.723
201612 -25.651 241.432 -32.701
201703 -25.908 243.801 -32.708
201706 -27.646 244.955 -34.738
201709 -26.208 246.819 -32.682
201712 -14.257 246.524 -17.800
201803 -16.022 249.554 -19.761
201806 -15.197 251.989 -18.562
201809 -14.989 252.439 -18.276
201812 -14.871 251.233 -18.219
201903 -16.150 254.202 -19.554
201906 -17.155 256.143 -20.614
201909 -18.198 256.759 -21.815
201912 -17.864 256.974 -21.396
202003 -2.218 258.115 -2.645
202006 -0.354 257.797 -0.423
202009 -0.127 260.280 -0.150
202012 -0.113 260.474 -0.134
202103 -0.095 264.877 -0.110
202106 -0.098 271.696 -0.111
202109 -0.105 274.310 -0.118
202112 -0.102 278.802 -0.113
202203 -0.111 287.504 -0.119
202206 -0.095 296.311 -0.099
202209 -0.097 296.808 -0.101
202212 -0.095 296.797 -0.099
202303 -0.085 301.836 -0.087
202306 -0.058 305.109 -0.059
202309 -0.044 307.789 -0.044

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


RespireRx Pharmaceuticals Business Description

Address 126 Valley Road, Suite C, Glen Rock, NJ, USA, 07452
RespireRx Pharmaceuticals Inc is engaged in the discovery, value-added development, and commercialization through partners of pharmaceuticals for the treatment of neurological and psychiatric disorders. The pipeline products of the company are dronabinol which is in a 505(b)(2) development ideas for the treatment of OSA (Obstructive Sleep Apnea), a form of sleep apnea; AMPAkines CX1739 for the treatment of bladder control and other conditions associated with spinal injury; CX717 for ADHD and CX1942 which is an injectable dosage formulation and GABAkines lead KRM-II-81 in preclinical development for treatment resistant epilepsy and non-opioid pain management.
12GF Score

Get the complete analysis for RSPI

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price